Trade Names:Advil- Tablets 200 mg
Trade Names:Advil Liqui-Gels- Capsules 200 mg
Trade Names:Advil Migraine- Capsules 200 mg
Trade Names:Children's Advil- Suspension 100 mg per 5 mL
Trade Names:Children's Motrin- Tablets, chewable 50 mg- Suspension 100 mg per 5 mL
Trade Names:Ibuprofen- Capsules 200 mg- Tablets 200 mg- Tablets 400 mg- Tablets 600 mg- Tablets 800 mg- Tablets, chewable 100 mg
Trade Names:Ibutab- Tablets 200 mg
Trade Names:Infant's Motrin- Oral drops 40 mg/mL
Trade Names:Junior Strength Motrin- Tablets 100 mg- Tablets, chewable 100 mg
Trade Names:Motrin Migraine Pain- Tablets 200 mg
Trade Names:PediaCare Fever- Suspension 100 mg per 5 mL- Oral drops 40 mg/mL
Trade Names:Pediatric Advil Drops- Suspension 100 mg per 2.5 mLApo-Ibuprofen (Canada)Apo-Ibuprofen Prescription (Canada)Motrin IB Extra Strength (Canada)Motrin IB Super Strength (Canada)
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
T max is 1 to 2 h. Bioavailability is less than 80%.
Plasma t ½ is 1.8 to 2 h. 45% to 79% is eliminated through the urine. Cl is 3 to 35 L/h.
Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, mild to moderate pain, primary dysmenorrhea, reduction of fever, migraine.
Treatment of perioperative pain in the setting of coronary artery bypass graft surgery; patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; hypersensitivity to any component of the product.
PO 300 to 800 mg 3 times daily to 4 times daily, not to exceed 3.2 g/day.Mild to Moderate PainAdults
PO 400 mg every 4 to 6 h as needed.Primary DysmenorrheaAdults
PO 400 mg every 4 h as needed.Fever ReductionChildren 1 to 12 yr of age
39.2°C (102.5°F) and less, recommended dose PO 5 mg/kg; more than 39.2°C (102.5°F), recommended dose PO 10 mg/kg; max daily dose 40 mg/kg.OTC Use (Minor Aches/Pains, Dysmenorrhea, Fever Reduction)
PO 200 mg every 4 to 6 h. Do not exceed 1.2 g in 24 h, or take for pain for more than 10 days or for fever for more than 3 days, unless directed by health care provider. Use smallest effective dose.OTC Use (Migraine)Adults
PO 400 mg with a glass of water. If symptoms persist or worsen, contact health care provider. Do not exceed 400 mg in 24 h or for longer than 10 days unless directed by health care provider.OTC Use (Children)
PO If possible, use weight to dose; otherwise, use age. May repeat dose every 6 to 8 h. Do not use more than 4 times per day.
Store at 68° to 77°F.
Antihypertensive effect of ACE inhibitors may be diminished.Aspirin
Protein binding of ibuprofen may be reduced; in addition, the risk of gastric erosion and bleeding may be increased.Beta-blockers
Antihypertensive effect may be decreased.Digoxin
Ibuprofen may increase digoxin serum levels.Diuretics
Diuretic effects may be decreased.Lithium
May increase lithium levels.Methotrexate
May increase methotrexate levels.Warfarin
May increase risk of gastric erosion and bleeding.
None well documented.
Edema, fluid retention (greater than 1% and less than 3%).
Dizziness (3% to 9%); headache, nervousness (greater than 1% and less than 3%).
Rash including maculopapular (3% to 9%); pruritus (greater than 1% and less than 3%).
Tinnitus (greater than 1% and less than 3%).
Epigastric pain, heartburn, nausea (3% to 9%); abdominal cramps or pain, abdominal distress, constipation, diarrhea, fullness of GI tract (bloating, flatulence), indigestion, nausea and vomiting (greater than 1% and less than 3%).
Decreased appetite (greater than 1% and less than 3%).
NSAIDs may cause an increased risk of serious CV thrombotic events, MI, and stroke, which can be fatal. This risk may increase with length of therapy. Patients with CV disease or risk factors for CV disease may be at greater risk. NSAIDs cause an increased risk of serious GI adverse reactions, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur any time during use and without warning symptoms. Elderly patients are at greater risk of serious GI events.
Follow chronically treated patients for signs and symptoms of GI tract ulceration and bleeding. Monitor LFTs periodically during long-term therapy. Monitor renal function in patients with compromised kidney function. Monitor Hgb in patients with low Hgb and hematocrit levels. Perform eye examinations if patient experiences visual disturbances. Closely monitor BP during the initiation of treatment and throughout the course of therapy. Carefully monitor patients who may be adversely affected by alterations in platelet function (eg, patients with coagulation disorders or receiving anticoagulant therapy).
Category C .
Increased risk of adverse reactions.
Use is not recommended in patients with advanced kidney disease. Long-term treatment with NSAIDs may result in renal papillary necrosis and other renal injury.
Use with caution in patients with fluid retention, hypertension, or heart failure.
Do not administer to patients with aspirin triad, which occurs typically in asthmatic patients who experience rhinitis with or with nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs.
Patients with asthma may have aspirin-sensitive asthma, which may be associated with severe and sometimes fatal bronchospasm. Ibuprofen should not be administered to patients with this type of aspirin-sensitivity because of possible cross-reactivity.
New hypertension or worsening of preexisting hypertension, either of which may contribute to increased risk of CV events, may occur.
NSAIDs inhibit platelet aggregation and have been reported to prolong bleeding time.
Serious and sometimes fatal skin adverse reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur.
Acute renal failure, apnea, cyanosis, drowsiness, epigastric pain, GI irritation/bleeding, lethargy, metabolic acidosis, nausea, sweating, tinnitus, vomiting.
Copyright © 2009 Wolters Kluwer Health.